298. 遺伝性膵炎
［臨床試験数：93，薬物数：168（DrugBank：51），標的遺伝子数：48，標的パスウェイ数：134］
Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02869893 (ClinicalTrials.gov) | August 10, 2016 | 5/6/2016 | MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics | Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics | Healthy Volunteers | Drug: Secretin | Children's Hospital Medical Center, Cincinnati | ChiRhoClin, Inc.;The National Pancreas Foundation | Completed | 6 Years | 15 Years | All | 57 | N/A | United States |
| 2 | NCT02458118 (ClinicalTrials.gov) | June 2012 | 27/5/2015 | Pancreatic Perfusion Using Secretin and MRI | Study to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Drug: Secretin | University of Nottingham | NULL | Recruiting | 18 Years | 80 Years | Both | 15 | Phase 1;Phase 2 | United Kingdom |
| 3 | NCT01265875 (ClinicalTrials.gov) | December 2010 | 22/12/2010 | Secretin Infusion for Pain Due to Chronic Pancreatitis | Secretin Infusion for Pain Due to Chronic Pancreatitis | Chronic Pancreatitis | Drug: Human Secretin | ChiRhoClin, Inc. | Dartmouth-Hitchcock Medical Center | Completed | 18 Years | 70 Years | All | 12 | Phase 1;Phase 2 | United States |
| 4 | NCT01452217 (ClinicalTrials.gov) | September 2010 | 10/10/2011 | Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers | The Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers | Chronic Pancreatitis | Drug: Secretin | University of Nottingham | NULL | Completed | 18 Years | 75 Years | Male | 12 | Phase 1 | United Kingdom |
| 5 | NCT00620919 (ClinicalTrials.gov) | February 2008 | 22/1/2008 | Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis | RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis | Chronic Pancreatitis | Drug: RG1068 (Synthetic Human Secretin) | Massachusetts General Hospital | NULL | Terminated | 18 Years | 90 Years | Both | 0 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00621283 (ClinicalTrials.gov) | February 2008 | 22/1/2008 | Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population | RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population | Acute Recurrent Pancreatitis;Chronic Pancreatitis | Drug: RG1068 (Synthetic Human Secretin) | Massachusetts General Hospital | NULL | Terminated | 2 Years | 18 Years | Both | 0 | Phase 1 | United States |